Michael J. Fox Foundation backs Ariadne Bio's non-hallucinogenic psychedelic for Parkinson's

Ariadne Bio, a new biotech focused on Parkinson's disease, has received backing from the Michael J. Fox Foundation. The partnership centers on a non‑hallucinogenic psychedelic candidate that the foundation hopes will address motor symptoms without the side effects of traditional psychedelics.

The company announced a fundraising campaign to advance the development of the therapy. While specific amounts were not disclosed, the effort aims to secure capital needed for pre‑clinical and early clinical work.

In addition to the funding support, Ariadne Bio entered a licensing agreement that will allow it to further develop and commercialize the candidate. The deal is expected to accelerate the path toward clinical trials and potential market entry.